From geneticliteracyproject.org
In 2017, the first immuno-oncology cell therapies, known as chimeric antigen receptor T cells, or CAR T, were approved by the U.S. Food and Drug Administration. Immuno-oncology cell therapy is a field that leverages the immune system by modifying, and thereby enhancing, immune cells to target cancer.
CAR-T therapies have had an unprecedented success in blood cancers, such as certain leukemias and lymphomas.
CAR T therapies have shown limited success in solid tumors, since they do not typically express a molecule on their surface that is unique to the solid tumor and not to normal tissue. This, coupled with the complex matrix in which cancer cells grow, makes it challenging to develop cellular therapies for solid tumors.
With 2022 coming to a close, we thought it would be interesting for our readers to take a look down … 2022 News Recap: A culmination of interesting news over the past 12 months.
Pregnancy is a joyous time. It can also be a time filled with nervousness or worries about the baby’s health. … Pregnancy: Should I Bank My Baby’s Umbilical Cord Blood?
There is so much planning that goes into having a baby. From conception to birth, you have so much to … Planning for Nine Months – Your Pregnancy & Your Baby
